

### **AMENDMENT TO THE CLAIMS**

This listing of claims will replace all prior versions, and listings, of claims in the application:

#### **Listing of Claims:**

1-49. (canceled)

50. (currently amended) A method for reducing restenosis following a vascular surgical procedure, the method comprising: locally administering to a human a biocompatible, non-biodegradable sustained release dosage form comprising a cytostatic amount of a free, ~~non-binding partner-associated~~ therapeutic agent dispersed in a polymer-containing matrix, ~~which~~ wherein said free therapeutic agent inhibits vascular smooth muscle cell migration, does not exhibit substantial cytotoxicity, and does not substantially inhibit protein synthesis.

51. (currently amended) The method of claim 50, wherein the free therapeutic agent comprises taxol.

52. (previously presented) The method of claim 50, wherein the vascular surgical procedure comprises placement of a stent.

53. (previously presented) The method of claim 50, wherein the vascular surgical procedure comprises angioplasty.

54. (currently amended) The method of claim 50, wherein the locally administering comprises administering the free therapeutic agent directly to vascular smooth muscle tissue.

55. (previously presented) The method of claim 50, wherein the locally administering occurs during or after the vascular procedure.